Zacks Research Has Bullish Forecast for WST FY2025 Earnings

West Pharmaceutical Services, Inc. (NYSE:WST) – Analysts at Zacks Research boosted their FY2025 earnings per share (EPS) estimates for West Pharmaceutical Services in a research note issued on Thursday, January 22nd. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings of $7.07 per share for the year, up from their prior forecast of $7.06. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.62 per share. Zacks Research also issued estimates for West Pharmaceutical Services’ Q4 2025 earnings at $1.82 EPS, Q2 2026 earnings at $1.92 EPS, Q4 2026 earnings at $2.01 EPS, FY2026 earnings at $7.52 EPS, Q1 2027 earnings at $1.67 EPS, Q2 2027 earnings at $2.27 EPS, Q3 2027 earnings at $2.30 EPS and FY2027 earnings at $8.51 EPS.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, October 23rd. The medical instruments supplier reported $1.96 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.29. West Pharmaceutical Services had a net margin of 16.29% and a return on equity of 18.16%. The business had revenue of $804.60 million for the quarter, compared to analyst estimates of $788.42 million. During the same quarter in the previous year, the firm posted $1.85 earnings per share. The firm’s revenue for the quarter was up 7.7% on a year-over-year basis.

A number of other equities research analysts also recently weighed in on the stock. Evercore ISI lifted their price target on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “outperform” rating in a research report on Thursday, October 23rd. Deutsche Bank Aktiengesellschaft set a $345.00 price objective on West Pharmaceutical Services and gave the company a “buy” rating in a report on Friday, October 24th. Morgan Stanley began coverage on West Pharmaceutical Services in a research report on Monday, December 1st. They set an “equal weight” rating and a $285.00 target price for the company. Weiss Ratings restated a “hold (c)” rating on shares of West Pharmaceutical Services in a research report on Friday, January 9th. Finally, Wall Street Zen raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research note on Saturday, December 20th. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, West Pharmaceutical Services currently has a consensus rating of “Buy” and an average price target of $335.78.

West Pharmaceutical Services Trading Down 4.4%

NYSE WST opened at $236.78 on Friday. West Pharmaceutical Services has a 12 month low of $187.43 and a 12 month high of $348.90. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.07. The stock has a 50 day moving average of $270.73 and a 200-day moving average of $260.59. The company has a market cap of $17.03 billion, a PE ratio of 35.08, a PEG ratio of 3.41 and a beta of 1.17.

West Pharmaceutical Services Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 4th. Stockholders of record on Wednesday, January 28th will be issued a $0.22 dividend. The ex-dividend date of this dividend is Wednesday, January 28th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.4%. West Pharmaceutical Services’s dividend payout ratio is 13.04%.

Hedge Funds Weigh In On West Pharmaceutical Services

A number of institutional investors have recently added to or reduced their stakes in the stock. CYBER HORNET ETFs LLC bought a new stake in shares of West Pharmaceutical Services during the second quarter worth $25,000. Vermillion & White Wealth Management Group LLC grew its position in West Pharmaceutical Services by 193.9% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 144 shares of the medical instruments supplier’s stock worth $32,000 after acquiring an additional 95 shares during the last quarter. SJS Investment Consulting Inc. increased its holdings in West Pharmaceutical Services by 1,842.9% in the 3rd quarter. SJS Investment Consulting Inc. now owns 136 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 129 shares in the last quarter. CVA Family Office LLC raised its position in West Pharmaceutical Services by 573.3% in the second quarter. CVA Family Office LLC now owns 202 shares of the medical instruments supplier’s stock valued at $44,000 after purchasing an additional 172 shares during the last quarter. Finally, Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of West Pharmaceutical Services during the third quarter valued at about $47,000. 93.90% of the stock is currently owned by institutional investors and hedge funds.

More West Pharmaceutical Services News

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Citi initiated coverage with a Buy, providing an independent institutional endorsement that can support demand for the shares and reinforce confidence in West’s strategic positioning. West Pharmaceutical Services (WST) Gets a Buy from Citi
• Positive Sentiment: Zacks Research upgraded WST to a Strong-Buy (Zacks Rank #1) and raised earnings estimates across multiple quarters and fiscal years, signaling improved analyst expectations for revenue/profitability and providing a near-term catalyst for buy-side interest. All You Need to Know About West Pharmaceutical (WST) Rating Upgrade to Strong Buy
• Positive Sentiment: Product launch: West unveiled the Synchrony S1 prefillable syringe at Pharmapack 2026 — a move that targets biologics, vaccines and home-care use and could expand its addressable market in combination products and drug-delivery systems. WST Launches Synchrony S1 Prefillable Syringe at Pharmapack
• Neutral Sentiment: Analysis piece discusses West’s expansion into biologic syringe systems and whether that reshapes its combination‑product competitive edge — useful context for investors assessing long‑term growth but not an immediate earnings surprise. Does West Pharmaceutical (WST) Expanding Into Biologic Syringe Systems Reshape Its Combination-Product Edge?
• Neutral Sentiment: Zacks included WST on thematic lists (top medical-supply names and income-stock lists) — a visibility boost that may attract income and thematic investors but is less of an immediate price catalyst than upgrades or product news. 4 Medical Supply Stocks Poised to Gain

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.